Gain new KOL insights on the latest events happening in Malignant melanoma (MM): expanded indication label for Bristol-Myers Squibb’s Opdivo plus Yervoy regimen for metastatic melanoma patients regardless of BRAF status; Philogen’s pivotal Phase III trials for Darleukin and Fibromun in patients with stage IIIB/C melanoma and the prospects of Provectus Biopharmaceuticals’ PV-10 in Phase III trial are also discussed.
Will Opdivo plus Yervoy combination therapy use increase significantly following BRAF V600 (wild-type & mutation-positive) label expansion?
Which patient subsets do KOLs think will benefit most from Opdivo plus Yervoy combination?
What are KOLs expecting from the two year survival data in CheckMate 069?
How successful do KOLs think Philogen’s Darleukin and Fibromun immunocytokines will be in melanoma?
What safety concerns do KOLs have with Darleukin/Fibromun and which combinations could hold the key to their success?
What are the prospects of Provectus’ PV-10 and how do KOLs view the inclusion of Imlygic as a comparator in Phase III study?